The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Allogene Therapeutics, Inc. | Common Stock | 019770106 | 5,772,103 | 1,798,163 | SH | SOLE | 1,798,163 | 0 | 0 | ||
Centessa Pharmaceuticals plc | Ordinary Shares | 152309100 | 31,297,271 | 3,931,818 | SH | SOLE | 3,931,818 | 0 | 0 | ||
Dyne Therapeutics, Inc. | Common Stock | 26818M108 | 27,594,667 | 2,074,787 | SH | SOLE | 2,074,787 | 0 | 0 | ||
Kinnate Biopharma, Inc. | Common Stock | 49705R105 | 5,232,420 | 2,207,772 | SH | SOLE | 2,207,772 | 0 | 0 | ||
Kronos Bio, Inc. | Common Stock | 50107A104 | 3,456,643 | 2,765,314 | SH | SOLE | 2,765,314 | 0 | 0 | ||
LianBio | Ordinary Shares | 53000N108 | 10,200,916 | 2,282,084 | SH | SOLE | 2,282,084 | 0 | 0 | ||
Ikena Oncology, Inc. | Common Stock | 45175G108 | 443,628 | 225,192 | SH | SOLE | 225,192 | 0 | 0 |